Last reviewed · How we verify
Azopt
At a glance
| Generic name | Azopt |
|---|---|
| Sponsor | Alcon Research |
| Target | Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Ocular hypertension
- Open-angle glaucoma
Common side effects
- Blurred vision
- Bitter, sour, or unusual taste
- Blepharitis
- Dermatitis
- Dry eye
- Foreign body sensation
- Headache
- Hyperemia
- Ocular discharge
- Ocular discomfort
- Ocular keratitis
- Ocular pain
Serious adverse events
- Stevens-Johnson syndrome (SJS)
- Toxic epidermal necrolysis (TEN)
Key clinical trials
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG) (PHASE4)
- Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt (PHASE3)
- Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azopt CI brief — competitive landscape report
- Azopt updates RSS · CI watch RSS
- Alcon Research portfolio CI